Fibrinolytic agents for the management of ST-segment elevation myocardial infarction.

摘要: Rapid reperfusion is the key treatment goal in patients with ST-segment elevation myocardial infarction (STEMI). The American College of Cardiology-American Heart Association (ACC-AHA) 2004 guidelines for management STEMI include recommendations pharmacologic use fibrinolytic agents. Fibrinolytic agents are preferred class because their ability to achieve and restore blood flow when administered within 12 hours symptom onset. Four approved United States-streptokinase, alteplase, reteplase, tenecteplase. Several clinical trials have demonstrated beneficial effects these therapies reducing mortality rates suspected acute infarction. Alteplase as an intravenous infusion. However, relatively long half-lives reteplase tenecteplase enable bolus administration, which may be more convenient less time consuming. Reteplase a double bolus, dosing does not depend on patient's weight; single weight based. Adherence ACC-AHA guidelines, well knowledge about available agents, essential physicians pharmacists make informed decisions regarding appropriate strategies.